

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/613,222
Filing Date	07/03/2003
First Named Inventor	Joseph RUBINFELD
Art Unit	1642
Examiner Name	Not yet assigned
Attorney Docket Number	12636-330.201

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W		MOMPARLER, RICHARD L., et al., "Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia," <i>Pharmac. Ther.</i> (1985) Vol. 30: pp. 277-286	
		PETTI, MARIA CONCETTA, et al., "Pilot Study of 5-Aza-2'-Deoxycytidine (Decitabine) in the Treatment of Poor Prognosis Acute Myelogenous Leukemia Patients: Preliminary Results," <i>Leukemia</i> (1993) Vol. 7, Suppl. Monograph 1: pp. 36-41	
		RICHEL, D.L., et al., "The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia," <i>Br. J. Cancer</i> (1991) 64:144-148	
		RIVARD, GEORGES F., et al., "Phase I Study on 5-AZA-2'-Deoxycytidine in Children with Acute Leukemia," <i>Leukemia Research</i> (1981) Vol. 5 No. 6: pp. 453-462	
		SCHWARTSMANN, G., et al., "Decitabine (5-AZA-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations," <i>Leukemia</i> (March 1997) Vol. 11, Suppl. 1: S28-S31	
		WIJERMANS, P., et al., "Low-Dose 5-Aza-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients," <i>Journal of Clinical Oncology</i> (March 2000) Vol. 18, No. 5: pp. 956-962	
		WIJERMANS, PW, et al., "Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome," <i>Leukemia</i> (March 1997) Vol. 11, Suppl. 1: S19-S23	

Examiner signature	<i>Harry R. Mital</i>	Date Considered	4/14/06
-----------------------	-----------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/613,222	
				Filing Date	07/03/2003	
				First Named Inventor	Joseph RUBINFELD	
				Art Unit	1642	
				Examiner Name	Not yet assigned	
Sheet	2	of	4	Attorney Docket Number		12636-330.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
GN		CS 269077	12/22/1963	Ceskoslovenska akademie ved, (Prag)		
GN		DE 1922702	05/03/1969	Ceskoslovenska akademie ved, (Prag)	Abstract	
GN		DE 2105468	02/05/1971	Ceskoslovenska akademie ved, (Prag)		
GN		EP 286958	04/06/1988	Merck Pg	Abstract	
GN		JP 05219974	02/13/1992	Mitsui Petrochem Ind Ltd	Abstract only	
GN		JP 2002223753	01/30/2001	Hitachi	Abstract	
GN		JP 2002370939	06/12/2001	Taisho Pharmaceutical Co. Ltd.	Abstract	
GN		JP 2003310293	04/26/2002	Mitsui Chemical Inc.	Abstract	
GN		PCT/US04/22367 International Search Report	07/20/2005	SuperGen, Inc.		
GN		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		
GN		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		
GN		WO 94/27632	06/01/1993	Nycomed Pharma A/S		
GN		WO 96/40165	06/07/1995	Pro-Neuron, Inc.		
GN		WO 99/01118	07/01/1997	Artherogenics, Inc.		
GN		WO 00/23112	10/19/1998	Methylgene, Inc.		
GN		WO 00/40269	01/05/1999	Clarence Lee		
GN		WO 00/74634 A2	06/03/1999	AU, Jessie, L., S.		
GN		WO 01/79164 A2	03/21/2000	Atherogenics, Inc.		
GN		WO 02/47611 A2	11/28/2000	Board of Regents of the University of Texas System		
GN		WO 02/053138 A2	01/02/2001	Shanahan-Prendergast, Elisabeth		

Examiner Signature	<i>[Signature]</i>	Date Considered	4/14/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/613,222	
				Filing Date	07/03/2003	
				First Named Inventor	Joseph RUBINFELD	
				Art Unit	1642	
				Examiner Name	Not yet assigned	
Sheet	3	of	4	Attorney Docket Number		12636-330.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
G		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		
		WO 02/085400 A1	04/24/2001	Supergen, Inc.		
		WO 03/020252 A2	09/05/2001	Oncopharm Corporation		
		WO 03/026574 A2	09/24/2001	AU, Jessie, L. -S.		
		WO 03/046190 A1	11/30/2001	Medigene Aktiengesellschaft		
		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 2003/087774 A3	04/12/2002	Curators of the University of Missouri		
		WO 03/092623 A2	05/02/2002	Wyeth Holdings Corporation		
		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		

Examiner Signature	<i>Gary Michael</i>	Date Considered	4/14/06
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial preference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	07/03/2003
				First Named Inventor	Joseph RUBINFELD
				Art Unit	1642
				Examiner Name	Not yet assigned
Sheet	4	of	4	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GN		VON HOFF, et al., "5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia," <i>Annals of Internal Medicine</i> (1976) 85(2), pages 237-245	GN

Examiner signature		Date Considered	6/14/06
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application No.	10/613,222
Filing Date	07/03/2003
First Named Inventor	Rubinfeld
Art Unit	1642
Examiner Name	Nickol
Attorney Docket No.	12636.330.201

Sheet 1 Of 2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No. 1	Document No.	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner's Initials	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁵ - Kind Code ⁵ (if known)				
GW		WO 02/069903	09/12/2002	Biocryst Pharmaceuticals, Inc.		
EXAMINER SIGNATURE		Gangzhu		DATE CONSIDERED	4/14/06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application No.	10/613,222	
				Filing Date	07/03/2003	
				First Named Inventor	Rubinfeld	
				Art Unit	1642	
				Examiner Name	Nickol	
Sheet	2	Of	2	Attorney Docket No.		12636.330.201

OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		GOFFIN, J. et al., "DNA methyltransferase inhibitors—state of the art", <i>Annals of Oncology</i> , 2002, pages 1699-1716, Vol. 13.	
GW		SHEIKHNEJAD, G. et al., "Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine", <i>J. Mol. Biol.</i> , 1999, pages 2021-2034, Vol. 285.	
GW		WIJERMANS, P. et al., "Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients", <i>Journal of Clinical Oncology</i> , March 2000, pages 956-962, Vol. 18, No. 5	
EXAMINER SIGNATURE			DATE CONSIDERED <div style="float: right; text-align: right;">4/14/06</div>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/613,222	
			Filing Date	July 3, 2003	
			First Named Inventor	Joseph Rubinfeld	
			Art Unit	1642	
			Examiner Name	Gary B. Nickol	
Sheet	1	of	1	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GW		ATTADIA et al. 5-aza-2'-deoxycytidine as a differentiation inducer in hemopoietic malignancies: preliminary observations on in vivo modulation of leukemia cell phenotype and correlations with clinical response. <i>Experimental Hematology</i> . 1988; Vol. 16: 530.	
		BROWN, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy. <i>Expert Rev Anticancer Ther</i> . 2004; 4(4): 501-510.	
		GILBERT, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation. <i>Clinical Cancer Research</i> . 2004; 10: 4589-4596.	
		HERMAN, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation. <i>The New England Journal of Medicine</i> . 2003; 349(21): 2042-2054.	
		KOZAR et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-aza-2'-deoxycytidine treatment in L1210 leukemia and B16F10 melanoma models in mice. <i>Clinical Cancer Research</i> . 2003; Vol. 9: 3124-3133.	
		LEONE, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. <i>Haematologica</i> . 2002; 87(12): 1324-1341.	
		LEONE, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clin Immunol</i> . 2003; 109(1): 89-102.	

Examiner signature	<i>Gary B. Nickol</i>	Date Considered	4/14/06
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.